SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation ... their professional network, aimed at building an inclusive, diverse community.

Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced that the United States Food and Drug ...

Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinib SAN FRANCISCO, ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients ...

Sands, M.D., Ph.D., president and chief executive officer of Nurix. “John’s experience commercializing the BTK inhibitor ibrutinib as well as his experience building commercial teams ahead of ...

M.D., co-founder and chief executive officer of Verve Therapeutics. “Building on this momentum, we are developing three lipid-lowering medicines each utilizing our proprietary GalNAc-LNP liver ...

A drop in estradiol and progesterone levels after menopause could increase cartilage aging and degeneration, leading to osteoarthritis, a study in mice suggests.

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

Amado, M.D., President, Head of Global Research and Development at Zai Lab. “Building on the promising ... company based in China and the United States. We are focused on discovering, developing ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...

Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue.1,2,3,4SPEVIGO's ...